Registration Dossier

Diss Factsheets

Administrative data

Description of key information

To avoid unnecessary (animal) testing, a comprehensive grouping and read-across concept has been developed amongst several molybdenum containing substances. Acute oral, inhalation and dermal toxicity studies are available for several but not all substances in the category. The following LD50s are therefore either based on test data for the substance in this dossier, or based on read-across within the category:

For molybdenum dioxide:

LD50 oral: > 2000 mg/kg  (based on study with this substance)

LD50 inhalation, 4h: > 5.1 g/m³ (based on study with this substance)

LD50 dermal: > 2000 mg/kg (estimated, based on category read-across)

Key value for chemical safety assessment

Additional information

To avoid unnecessary (animal) testing, a comprehensive grouping and read-across concept has been developed amongst several molybdenum containing substances. This grouping/category approach is described in detail in a separate report (attached to IUCLID section 13), in accordance with the ECHA's "Read-Across Assessment Framework" (RAAF). The main conclusion is that read-across/grouping of molybdenum substances is justified for systemic effects, including acute toxicity, based on the formation of the molybdate ion from all substances in the category, as the driver for any systemic toxicity. Non common compounds formed from each substance, including those from “counter ions”, impurities or minor constituents, do not contribute significantly to the toxicity. For details, see “read-across document” in IUCLID section 13.

Justification for classification or non-classification

The registered substance does not require hazard classification for acute toxicity, based on substance specific test data or based on a category/read-across approach.